All In Biotech

Drug Trial Radar · NCT03361748

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: May 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

149

Actual

Start

Dec 13, 2017

Primary completion

Dec 20, 2023

Study completion Dec 20, 2023

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Dec 5, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture bb2121 chimeric antigen receptor (CAR) modified T cells. Prior to bb2121 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.

Conditions

  • Multiple Myeloma

Interventions

  • bb2121Biological

    : bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA02 CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response RateTime frame: From first dose to 24 Months

Locations

48 sites in 8 countries. Site status is shown where the registry gives one.

  • Local Institution - 108

    San Francisco, California

  • University of California - San Francisco

    San Francisco, California

  • Emory University

    Atlanta, Georgia

  • Local Institution - 103

    Atlanta, Georgia

  • Local Institution - 107

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Local Institution - 106

    Boston, Massachusetts

  • Local Institution - 105

    Rochester, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Local Institution - 102

    Hackensack, New Jersey

  • Local Institution - 109

    New York, New York

  • Mt. Sinai Medical Center

    New York, New York

  • Local Institution - 101

    Nashville, Tennessee

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Local Institution - 104

    Dallas, Texas

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Local Institution - 201

    Leuven, Belgium

  • Universitaire Ziekenhuizen Leuven

    Leuven, Flemish Brabant, Belgium

  • Princess Margaret Cancer Centre

    Toronto, Canada

  • Local Institution - 301

    Toronto, Ontario, Canada

  • Local Institution - 402

    Lille, France

  • Local Institution - 401

    Nantes, France

  • Centre Hospitalier Regional Universitaire de Lille-Hopital Calude Huriez Service des Maladies du Sang

    Lille, Hauts-de-France, France

  • Centre Hospitalier Universitaire de Nantes - Hotel Dieu

    Nantes, Pays de la Loire Region, France

  • Local Institution - 502

    Heidelberg, Germany

  • Local Institution - 503

    Tübingen, Germany

  • Local Institution - 501

    Würzburg, Germany

  • Universitatsklinikum Heidelberg Medizinische Klinik Krehl-Klinik Haematologie, Onkologie, Rheumato

    Heidelberg, Baden-Wurttemberg, Germany

  • University of Tübingen

    Tübingen, Baden-Wurttemberg, Germany

  • Universitatsklinikum Würzburg

    Würzburg, Bavaria, Germany

  • Local Institution - 602

    Bergamo, Italy

  • Ospedali Riuniti di Bergamo

    Bergamo, Italy

  • Local Institution - 601

    Bologna, Italy

  • Azienda Ospedaliero Universitaria Di Bologna Policlinico

    Bologna, Emilia-Romagna, Italy

  • Local Institution - 803

    Isehara City, Kanagawa, Japan

  • Local Institution - 801

    Shibuya-ku, Japan

  • Local Institution - 802

    Shimotsuke, Japan

  • Local Institution - 804

    Shinjuku, Japan

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.